Group 1 - The company's revenue from its generic drug business decreased to 802 million yuan in 2024, a year-on-year decline of 21.18%, with a net profit attributable to shareholders of -53 million yuan, down 119.39% [1] - In Q1 2025, the company reported revenue of 129 million yuan, with a net profit attributable to shareholders of -26 million yuan [1] - Revenue breakdown for 2024 includes: preclinical pharmaceutical research income of 194 million yuan (-42.8%), clinical services income of 213 million yuan (+10.5%), self-developed results transformation income of 288 million yuan (-26.7%), equity sharing income of 8 million yuan (-71.3%), and commercial production income of 37 million yuan [1] Group 2 - As of the end of 2024, the company has nearly 300 self-developed projects that have been established but not yet transformed, with 91 projects completed in the small trial stage, 53 in the pilot scale-up stage, and 78 in the verification production stage [2] - The company has achieved 58 technology transformations of research results in 2024, with over 200 personnel in the new drug research and development team [2] - The company emphasizes its integrated drug development capabilities, combining pharmaceutical research, clinical trials, and customized R&D production, along with a comprehensive production service from intermediates to active pharmaceutical ingredients to formulations [2] Group 3 - The company forecasts revenues for 2025-2027 to be 704 million yuan, 778 million yuan, and 875 million yuan, representing year-on-year changes of -12.2%, +10.6%, and +12.4% respectively [3] - The net profit attributable to shareholders is projected to be 55 million yuan, 103 million yuan, and 119 million yuan for 2025-2027, with year-on-year growth rates of 204.4%, 87.9%, and 15.0% respectively [3] - The company anticipates short-term performance uncertainty due to policy impacts but expects to turn a profit by 2025, leading to a revised "accumulate" rating [3]

百诺医药在资本市场上有丰富的经历。 IPO日报注意到，百诺医药曾于2016年3月24日登陆新三板挂牌，证券简称为百诺医药，证券代码为 836534，挂牌6年半后，在 2022年12月16日摘牌。 星标 ★ IPO日报 精彩文章第一时间推送 4月17日晚间，证监会官网披露，中信建投对辅导山东百诺医药股份有限公司（下称"百诺医药"）挂牌新三板并在北交所上市进 行了备案登记。 两年多前曾从新三板摘牌，后又创业板IPO失败，如今想重回新三板并在北交所上市的百诺医药怎么样了？ IPO日报注意到，百诺医药的2021年-2023 年营业收入和净利润的年复合增长率分别为43.98％、123.61％，业绩极为亮眼，毛 利率也高达76%以上。 制图：佘诗婕 净利润年复合增长率123.61％ 据悉，百诺医药成立于2000年8月，是一家贯穿药物研发及生产全生命周期的创新型一站式药物研发成果转化运营商，主要业务 分为三大部分，分别为医药研发CRO业务、医药生产CMO业务和原料药生产及销售业务，其中CRO业务以研发成果转化模式为 主。 （ Contract Research Organization ，即合同研究组织，指对外提供专业化药 ...